NMN/NR and SSRIs (Sertraline, Escitalopram): Interaction Guide

What are NMN and NR?

NMN and NR are oral dietary supplements, not FDA-approved drugs [10]. Both are precursors the body converts to NAD+, a coenzyme in cellular energy metabolism and a substrate for sirtuins and PARP enzymes [11]. The human trials below measured blood NAD+ and safety outcomes such as adverse events and laboratory tests [4][5]. None of them was designed as a drug-interaction study.

What does the sertraline label say about serotonin syndrome?

The Zoloft label calls serotonin syndrome a potentially life-threatening condition that sertraline can precipitate, and says it can occur when the drug is used alone [2]. It says the risk rises with other serotonergic drugs, naming triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines and St. John's wort, and that MAOIs are contraindicated [2]. Labeled signs include mental status changes such as agitation and hallucinations, autonomic instability such as tachycardia, diaphoresis and hyperthermia, neuromuscular findings such as tremor, rigidity, myoclonus and hyperreflexia, plus seizures and gastrointestinal symptoms [2].

How sertraline and escitalopram differ

The Zoloft label describes sertraline as a CYP2D6 inhibitor that may raise exposure to CYP2D6 substrates such as propafenone, flecainide, atomoxetine, desipramine, dextromethorphan and metoprolol [2]. Sertraline's half-life is about 26 hours; its desmethyl metabolite runs 62 to 104 hours and is much less active [2].

Escitalopram is cleared mainly by CYP3A4 and CYP2C19 [3]. The Lexapro label reports that escitalopram 20 mg/day for 21 days raised desipramine AUC by 100% (Cmax 40%) and metoprolol AUC by 82% (Cmax 50%) [3]. These are data on other drugs, not on NMN or NR.

What the NMN and NR trials measured

• NMN 250 mg/day for 12 weeks in 30 healthy adults (15 NMN, 15 placebo): whole-blood NAD+ rose, with no abnormalities on physiological or laboratory testing and no obvious adverse effects [4].
• NMN 300, 600 or 900 mg/day for 60 days in 80 middle-aged adults: blood NAD rose in every NMN group, highest at 600 and 900 mg, with no safety issues on adverse-event, laboratory and clinical monitoring [5].
• NMN 1,250 mg/day for up to 4 weeks in 31 adults aged 20 to 65: no severe adverse events and no changes beyond normal physiological variation in hematology, biochemistry, urine or body composition [6].
• NR 1,000 mg/day (500 mg twice daily) in a 2 by 6-week crossover with 24 completers aged 55 to 79: PBMC NAD+ about 60% above placebo; mild adverse events included nausea, flushing, leg cramps and bruising, with no serious events [7].
• NR 2,000 mg/day for 12 weeks in 40 sedentary obese men: no serious adverse events, normal safety blood tests [8].
• NR 3,000 mg/day for 4 weeks in 20 people with Parkinson's disease: no moderate or severe adverse events [9].

These doses are the ones studied, not recommended doses. There is no official RDA, upper limit or FDA-endorsed dose for NMN or NR. Pregnancy, breastfeeding, childhood, cancer, kidney disease and liver disease were not studied in these trials, so safety in those groups is unknown [1].

Regulatory status, briefly

NMN is sold in the US as an oral dietary supplement and is not an FDA-approved drug [10]. FDA reportedly took the position in 2022 that NMN could not be marketed as a supplement, because it had first been authorized for investigation as a new drug. In its 2025-09-29 response to a citizen petition, FDA reversed that view, finding evidence that NMN was marketed as a supplement beforehand. Reports of that letter say NMN may now be lawfully marketed as a dietary supplement under new-dietary-ingredient notification rules [10][12].